115 related articles for article (PubMed ID: 36165021)
21. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
[TBL] [Abstract][Full Text] [Related]
22. Establishment, characterization, and successful adaptive therapy against human tumors of NKG cell, a new human NK cell line.
Cheng M; Ma J; Chen Y; Zhang J; Zhao W; Zhang J; Wei H; Ling B; Sun R; Tian Z
Cell Transplant; 2011; 20(11-12):1731-46. PubMed ID: 21669033
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of CD28-mediated natural cytotoxicity by KIR2DL2 does not require p56(lck) in the NK cell line YT-Indy.
Tarazona R; Borrego F; Galiani MD; Aguado E; Peña J; Coligan JE; Solana R
Mol Immunol; 2002 Jan; 38(7):495-503. PubMed ID: 11750651
[TBL] [Abstract][Full Text] [Related]
24. Suppressive effect of asbestos on cytotoxicity of human NK cells.
Nishimura Y; Kumagai N; Maeda M; Hayashi H; Fukuoka K; Nakano T; Miura Y; Hiratsuka J; Otsuki T
Int J Immunopathol Pharmacol; 2011; 24(1 Suppl):5S-10S. PubMed ID: 21329559
[TBL] [Abstract][Full Text] [Related]
25. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
[TBL] [Abstract][Full Text] [Related]
26. TCGF (IL 2)-receptor inducing factor(s). I. Regulation of IL 2 receptor on a natural killer-like cell line (YT cells).
Yodoi J; Teshigawara K; Nikaido T; Fukui K; Noma T; Honjo T; Takigawa M; Sasaki M; Minato N; Tsudo M
J Immunol; 1985 Mar; 134(3):1623-30. PubMed ID: 2578514
[TBL] [Abstract][Full Text] [Related]
27. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
28. Immunological characterization of glioblastoma cells for immunotherapy.
Jung TY; Choi YD; Kim YH; Lee JJ; Kim HS; Kim JS; Kim SK; Jung S; Cho D
Anticancer Res; 2013 Jun; 33(6):2525-33. PubMed ID: 23749904
[TBL] [Abstract][Full Text] [Related]
29. Involvement of natural cytotoxicity receptors in human natural killer cell-mediated lysis of neuroblastoma and glioblastoma cell lines.
Sivori S; Parolini S; Marcenaro E; Castriconi R; Pende D; Millo R; Moretta A
J Neuroimmunol; 2000 Jul; 107(2):220-5. PubMed ID: 10854660
[TBL] [Abstract][Full Text] [Related]
30. Effect of interleukin 1 on the expression of interleukin 2 receptor (Tac antigen) on human natural killer cells and natural killer-like cell line (YT cells).
Shirakawa F; Tanaka Y; Eto S; Suzuki H; Yodoi J; Yamashita U
J Immunol; 1986 Jul; 137(2):551-6. PubMed ID: 3013994
[TBL] [Abstract][Full Text] [Related]
31. Human natural killer cell line modified with a chimeric immunoglobulin T-cell receptor gene leads to tumor growth inhibition in vivo.
Schirrmann T; Pecher G
Cancer Gene Ther; 2002 Apr; 9(4):390-8. PubMed ID: 11960290
[TBL] [Abstract][Full Text] [Related]
32. Natural killer cells kill extracellular Pseudomonas aeruginosa using contact-dependent release of granzymes B and H.
Feehan DD; Jamil K; Polyak MJ; Ogbomo H; Hasell M; Li SS; Xiang RF; Parkins M; Trapani JA; Harrison JJ; Mody CH
PLoS Pathog; 2022 Feb; 18(2):e1010325. PubMed ID: 35202434
[TBL] [Abstract][Full Text] [Related]
33. NK cells impede glioblastoma virotherapy through NKp30 and NKp46 natural cytotoxicity receptors.
Alvarez-Breckenridge CA; Yu J; Price R; Wojton J; Pradarelli J; Mao H; Wei M; Wang Y; He S; Hardcastle J; Fernandez SA; Kaur B; Lawler SE; Vivier E; Mandelboim O; Moretta A; Caligiuri MA; Chiocca EA
Nat Med; 2012 Dec; 18(12):1827-34. PubMed ID: 23178246
[TBL] [Abstract][Full Text] [Related]
34. Leucine rich repeats and calponin homology domain containing 1 inhibits NK-92 cell cytotoxicity through attenuating Src signaling.
Dai K; Chen Z; She S; Shi J; Zhu J; Huang Y
Immunobiology; 2020 May; 225(3):151934. PubMed ID: 32173150
[TBL] [Abstract][Full Text] [Related]
35. shp-2 gene knockout upregulates CAR-driven cytotoxicity of YT NK cells.
Subrakova VG; Kulemzin SV; Belovezhets TN; Chikaev AN; Chikaev NA; Koval OA; Gorchakov AA; Taranin AV
Vavilovskii Zhurnal Genet Selektsii; 2020 Feb; 24(1):80-86. PubMed ID: 33659784
[TBL] [Abstract][Full Text] [Related]
36. CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.
Burger MC; Zhang C; Harter PN; Romanski A; Strassheimer F; Senft C; Tonn T; Steinbach JP; Wels WS
Front Immunol; 2019; 10():2683. PubMed ID: 31798595
[TBL] [Abstract][Full Text] [Related]
37. NK cells with KIR2DS2 immunogenotype have a functional activation advantage to efficiently kill glioblastoma and prolong animal survival.
Gras Navarro A; Kmiecik J; Leiss L; Zelkowski M; Engelsen A; Bruserud Ø; Zimmer J; Enger PØ; Chekenya M
J Immunol; 2014 Dec; 193(12):6192-206. PubMed ID: 25381437
[TBL] [Abstract][Full Text] [Related]
38. Functional dichotomy in natural killer cell signaling: Vav1-dependent and -independent mechanisms.
Colucci F; Rosmaraki E; Bregenholt S; Samson SI; Di Bartolo V; Turner M; Vanes L; Tybulewicz V; Di Santo JP
J Exp Med; 2001 Jun; 193(12):1413-24. PubMed ID: 11413196
[TBL] [Abstract][Full Text] [Related]
39. Transgenic expression of HLA-E single chain trimer protects porcine endothelial cells against human natural killer cell-mediated cytotoxicity.
Lilienfeld BG; Crew MD; Forte P; Baumann BC; Seebach JD
Xenotransplantation; 2007 Mar; 14(2):126-34. PubMed ID: 17381687
[TBL] [Abstract][Full Text] [Related]
40. CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide.
Gurney M; Stikvoort A; Nolan E; Kirkham-McCarthy L; Khoruzhenko S; Shivakumar R; Zweegman S; Van de Donk NWCJ; Mutis T; Szegezdi E; Sarkar S; O'Dwyer M
Haematologica; 2022 Feb; 107(2):437-445. PubMed ID: 33375774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
